February 19, 2014

A Focus on Lung Cancer WCLC Consumer Forum

Lung Foundation Australia held a consumer forum at the World Conference on Lung Cancer in Sydney on Sunday, 27th October 2013.

This was a great opportunity for patients, carers and their families to participate in an informal, question and answer session with World leaders in lung cancer research, treatment, care and advocacy.

This forum was facilitated by Ms Kay Stammers who is a professional health journalist.

Topics presented and discussed were:

Session 1 – Standardising Lung Cancer around the World – presented by Dr David Carbone MD PhD – USA

Dr David Carbone is Professor of Internal Medicine, and currently Director of the James Thoracic Center at the Ohio State University.  His eminent research career centres around research projects and publications focused on lung cancer, and specifically proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy.  Recent research directions include development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and preneoplasias to guide the development of novel therapeutics, especially using mass spectrometry-based proteomics.

Session 2 – Tackling Lung Cancer in Australia – improving patient outcomes – presented by Ms Liz King, AUS

Ms Liz King is the Manager of the Lung Cancer program at Cancer Australia.  Her role is to co-ordinate the delivery of Cancer Australia’s lung cancer program of work, designed to build the evidence base with a focus on the uptake of best practice lung cancer care, to improve outcomes for people with lung cancer.

Liz has over eighteen years’ experience delivering health program and service delivery outcomes within national, state and non-government sectors.

Session 3 – Lung Cancer Screening – where are we at? – presented by Dr Henry Marshall, AUS

Dr Henry Marshall is a lung specialist and Research Fellow at the Prince Charles Hospital, and University of Queensland Thoracic Research Centre, Brisbane.  He works extensively with patients with lung cancer and has a special interest in early detection.  He is an investigator in the Queensland Lung Cancer Screening study (QLCSS), the only CT screening study in Australia to date.

Session 4 – Advances in Diagnosing Lung Cancer – presented by Dr Annabelle Mahar, AUS

Dr Annabelle Mahar is a pathologist at the Royal Prince Alfred Hospital Pathology and specialises in Tissue Pathology and Diagnostic Oncology

Special Interests: Pulmonary Pathology, Soft Tissue and Bone pathology, Cytology

Dr Mahar graduated from the University of Adelaide and trained at the Institute and Medical Veterinary Science, followed by a fellowship in pulmonary pathology at Duke University Medical Center.  She is an active participant in weekly Multidisciplinary Thoracic Oncology and Bone and Soft Tissue Tumour Meetings and twice monthly Interstitial Lung Disease meetings at Royal Prince Alfred Hospital.  She is a member of the Australasian Idiopathic Pulmonary Fibrosis Registry steering committee.

Session 5 – Advances in Lung Cancer Treatments – presented by Dr David Carbone MD PhD, USA

Dr David Carbone is Professor of Internal Medicine, and currently Director of the James Thoracic Center at the Ohio State University.  His eminent research career centres around research projects and publications focused on lung cancer, and specifically proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy.  Recent research directions include development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and preneoplasias to guide the development of novel therapeutics, especially using mass spectrometry-based proteomics. 

Session 6 – Patients Powering Progress – presented by Ms Bonnie J Addario, USA

Ms Bonnie J. Addario, the Founder and Chair of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), a San Francisco-based, international non-profit organization, is a nine-year Lung Cancer survivor. Through her visionary leadership and passion, the Foundation has become recognized as one of the world’s largest philanthropy devoted exclusively to eradicating Lung Cancer.

BJALCF’s commitment to its patients is to collaborate and partner with the leaders in oncology, technology, science, medicine and philanthropy to make lung cancer a chronically managed disease within 10 years.

Bonnie founded the Addario Lung Cancer Medical Institute dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients.

She is committed to changing the horrific statistics and mortality rates for Lung Cancer.

Session 7 Q&A Session – The expert panel answers questions from the audience